Efficacy, safety and pharmacology of oral ASN002, a novel Jak/Syk inhibitor, in moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled study

被引：0
|
作者：
Guttman-Yassky, N. A. [1 ]
Maari, N. A. [2 ]
Forman, N. A. [3 ]
Bhatia, N. A. [4 ]
Lee, N. A. [5 ]
Fowler, N. A. [6 ]
Tyring, N. A. [7 ]
Pariser, N. A. [8 ]
Sofen, N. A. [9 ]
Dhawan, N. A. [10 ]
Zook, N. A. [11 ]
Estrada, N. A. [12 ]
Pavel, N. A. [12 ]
Zammit, J. [13 ]
Sarper, N. A. [13 ]
Rao, N. A. [13 ]
Bissonnette, N. A. [2 ]
机构：
[1] Mt Sinai Med Ctr, Icahn Sch Med, Dermatol, New York, NY 10029 USA
[2] Innovaderm Res Inc, Montreal, ON, Canada
[3] Forward Clin Trials, Tampa, FL USA
[4] TCR Med Corp, San Diego, CA USA
[5] Progress Clin Res PA, San Antonio, TX USA
[6] DS Res, Louisville, KY USA
[7] Ctr Clin Studies Ltd LLP, Houston, TX USA
[8] Virginia Clin Res Inc, Norfolk, VA USA
[9] Dermatol Res Associates, Los Angeles, CA USA
[10] Ctr Dermatol Clin Res Inc, Fremont, CA USA
[11] Olympian Clin Res, Tampa, FL USA
[12] Mt Sinai Med Ctr, Icahn Sch Med, New York, NY 10029 USA
[13] Asana Biosci, Princeton, NJ USA
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2018年 / 179卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P063
引用
收藏
页码：E40 / E41
页数：2
相关论文
共 50 条
  • [1] The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled study
    Bissonnette, R.
    Maari, C.
    Forman, S.
    Bhatia, N.
    Lee, M.
    Fowler, J.
    Tyring, S.
    Pariser, D.
    Sofen, H.
    Dhawan, S.
    Zook, M.
    Zammit, D. J.
    Usansky, H.
    Denis, L.
    Rao, N.
    Song, T.
    Pavel, A. B.
    Guttman-Yassky, E.
    BRITISH JOURNAL OF DERMATOLOGY, 2019, 181 (04) : 733 - 742
  • [2] The efficacy and safety of dupilumab in Chinese patients with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled study
    Zhao, Y.
    Wu, L.
    Lu, Q.
    Gao, X.
    Zhu, X.
    Yao, X.
    Li, L.
    Li, W.
    Ding, Y.
    Song, Z.
    Liu, L.
    Dang, N.
    Zhang, C.
    Liu, X.
    Gu, J.
    Wang, J.
    Geng, S.
    Liu, Q.
    Guo, Y.
    Dong, L.
    Su, H.
    Bai, L.
    O'Malley, J. T.
    Luo, J.
    Laws, E.
    Mannent, L.
    Ruddy, M.
    Amin, N.
    Bansal, A.
    Ota, T.
    Wang, M.
    Zhang, J.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : 633 - 641
  • [3] ASN002 a dual oral inhibitor of JAK/SYK signaling improves clinical outcomes and associated cutaneous inflammation in moderate-to-severe atopic dermatitis patients
    Guttman-Yassky, E.
    Pavel, A. B.
    Song, T.
    Kim, H.
    Zammit, D.
    Toker, S.
    Rao, N.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2018, 138 (05) : S95 - S95
  • [4] Efficacy and Safety of Baricitinb in a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study in Pediatric Patients with Moderate-to-Severe Atopic Dermatitis
    Torrelo, A.
    Rewerska, B.
    Paller, Amy
    Prakash, A.
    Zhu, D.
    Pontes, M.
    Wu, Wen-Shuo
    Eichenfield, Lawrence F.
    Boecker, Ulrike
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 99 - 99
  • [5] Risankizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
    Tyring, Stephen K. K.
    Rich, Phoebe
    Tada, Yayoi
    Beeck, Stefan
    Messina, Izabella
    Liu, Jie
    Huang, Xiaohong
    Shumack, Stephen
    DERMATOLOGY AND THERAPY, 2023, 13 (02) : 595 - 608
  • [6] Risankizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
    Stephen K. Tyring
    Phoebe Rich
    Yayoi Tada
    Stefan Beeck
    Izabella Messina
    Jie Liu
    Xiaohong Huang
    Stephen Shumack
    Dermatology and Therapy, 2023, 13 : 595 - 608
  • [7] Efficacy and Safety of GR1802 in Patients With Moderate-to-Severe Atopic Dermatitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial
    Wang, Shangshang
    Zhang, Litao
    Liang, Yunsheng
    Zhang, Shifa
    Wang, Jingyan
    Man, Xiaoyong
    Ji, Chao
    Chen, Rixin
    Xiang, Guang
    Meng, Zudong
    Yang, Chunjun
    Cheng, Hao
    Wang, Qi
    Li, Lin-feng
    Zhang, Siping
    Ding, Yanfeng
    Zhu, Quangang
    Qin, Lanying
    Li, Yumei
    Lu, Qianjin
    Xia, Li
    Cao, Shuanglin
    Yu, Chunshui
    Duan, Xinsuo
    Wu, Liming
    Zhang, Chunlei
    Jiang, Congjun
    Wang, Wei
    Xu, Jinhua
    DERMATOLOGIC THERAPY, 2025, 2025 (01)
  • [8] Dupilumab Monotherapy in Adults with Moderate-to-Severe Atopic Dermatitis: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study
    Bieber, Thomas R. M.
    Thaci, Diamant
    Graham, Neil
    Pirozzi, Gianluca
    Teper, Ariel
    Ren, Haobo
    Radin, Allen
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2014, 133 (02) : AB404 - AB404
  • [9] Killed Mycobacterium vaccae suspension in children with moderate-to-severe atopic dermatitis:: a randomized, double-blind, placebo-controlled trial
    Berth-Jones, J.
    Arkwright, P. D.
    Marasovic, D.
    Savani, N.
    Aldridge, C. R.
    Leech, S. N.
    Morgan, C.
    Clark, S. M.
    Ogilvie, S.
    Chopra, S.
    Harper, J. I.
    Smith, C. H.
    Rook, G. A. W.
    Friedmann, P. S.
    CLINICAL AND EXPERIMENTAL ALLERGY, 2006, 36 (09): : 1115 - 1121
  • [10] Efficacy and safety of dupilumab with concomitant topical corticosteroids in Japanese pediatric patients with moderate-to-severe atopic dermatitis: A randomized, double-blind, placebo-controlled phase 3 study
    Ebisawa, Motohiro
    Kataoka, Yoko
    Tanaka, Akio
    Nagao, Mizuho
    Laws, Elizabeth
    Mortensen, Eric
    Nawata, Hisakatsu
    Arima, Kazuhiko
    Watanabe, Daisuke
    Lu, Xin
    Maloney, Jennifer
    Dubost-Brama, Ariane
    Bansal, Ashish
    Yahata, Kenji
    ALLERGOLOGY INTERNATIONAL, 2024, 73 (04) : 532 - 542
12345